1. Sponsor: Alto Neuroscience
Protocol Number: ALTO-100-201
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder
Inclusion Criteria:
Exclusion Criteria:
2. Sponsor: DeNovo Biopharma LLC
Protocol Number: DB104-01
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment Resistant Depression
Inclusion Criteria:
Protocol Number: SEP361-226
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder
Inclusion criteria:
Protocol Number: NBI-98854-ATS3019 & NBI-1065844-CIAS2023
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Inclusion criteria:
Protocol Number: BHV4157-302
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Inclusion criteria:
Protocol Number: 3110-305-002 & M21-201
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)
Inclusion criteria:
Sponsor: Abbvie Pharmaceuticals
Protocol Number: 20-AVP-786-306
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type
Inclusion criteria: